UNSPSC 51351914: Etynodiol diacetate

This classification denotes a therapeutic progestin with the molecular formula C24H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62H10A1236, chemically known as 19-norpregn-4-en-20-yne-3,17-diol, diacetate, (3.beta.,17.alpha.)- but more generally known as ethynodiol diacetate, which bears US NIH Compound Identifier 3304. European Medicines Agency schedules Etynodiol diacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02051MIG.

Most nations, for tariff and trade purposes, schedule etynodiol diacetate under HS 29372300 and SITC 54153. SMILES: CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C.

UNSPSC 51351914 Etynodiol diacetate, a Commodity code, covers hormonal contraceptive pharmaceuticals sourced through state and local cooperative purchasing vehicles and direct government procurement. Recent activity shows state and local governments acquiring etynodiol diacetate and related generic pharmaceuticals through multi-source supplier agreements, with pricing, product availability, and supply-chain compliance as primary evaluation drivers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body for this commodity class, leveraging cooperative purchasing to aggregate demand across participating state and local government facilities. MMCAP's procurement model distributes products through authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co., LLC) rather than direct government purchase, placing manufacturers at the supply-chain tier responsible for NDC-level product certification, cGMP and Drug Supply Chain Security Act compliance, and wholesale-chargeback pricing structures.

MMCAP's January 2026 Request for Proposal for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, represents the most recent and concrete opportunity under this code. The procurement covers multiple participating jurisdictions including Minnesota and Oregon, with contract awards effective July 1, 2026, for a two-year initial term with optional extensions. Evaluation is heavily weighted toward price competitiveness (75 percent), with secondary criteria including fixed pricing, EDI capability, administrative-fee compliance, and pricing-format flexibility (net price, WAC-minus, or flat-price options). Vendors must maintain comprehensive insurance ($5,000,000 general liability, $2,000,000 network security and privacy liability, $2,000,000 professional liability), hold contractual relationships with at least two of the three authorized wholesalers, and deliver all products with expiration dates at least one year from manufacture and a minimum six-month shelf life. The RFP does not identify specific set-aside designations or business-classification restrictions.